
News|Articles|September 1, 2001
Trio of new studies help clarify role of abciximab
Abciximab reduces nonfatal outcomes as part of a new reperfusion regimen for acute myocardial infarction (MI) but appears not to benefit patients with acute coronary syndromes who don't undergo early revascularization.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
The trend toward post-infusion outpatient care of patients treated with CAR-T | ASH 2025
2
Sanofi’s Qfitlia seems favorable for hemophilia with easier dosing and broad coverage | ASH 2025
3
Immunotherapy combination of teclistamab and daratumumab heralded as potential 'functional cure' for multiple myeloma | ASH 2025
4
2025 FDA dermatology approvals: A new gene therapy and two targeted therapies
5





















































